Peptides: one catalog, very different evidence states
First published
Updated
Product, indication, population, endpoint and follow-up all matter
A catalog of compounds looks uniform because every row has the same shape. The evidence behind those rows is not uniform. This note separates mechanism, human findings, regulatory decisions and product quality before reproducing the complete catalog, which keeps its own risk levels and verification caveats.
The category hides different evidence states
The compound catalog below is broad. A shared catalog heading does not mean every entry has comparable human evidence, regulatory status or product quality. Those questions have to be answered for the particular molecule, formulation and proposed use.
A biological mechanism is a starting point for research, not proof of a useful treatment. A substance can affect a pathway without demonstrating a meaningful patient outcome. Reporting that distinction is especially important when commercial claims move directly from mechanism to promised benefit.
Human data also vary in strength. A small observation and a randomized trial are not interchangeable, and a trial's endpoint matters. A result for one condition cannot be silently extended to general wellness or a different patient population.
Approval is similarly specific. The FDA's Forzinity announcement identifies a product, indication and eligible population. It does not approve all substances with a similar mechanism or every product using the same molecule's name. [1]
A specific approval, not a class endorsement
On September 19, 2025, FDA announced accelerated approval of Forzinity, an elamipretide injection, for Barth syndrome in patients weighing at least 30 kilograms. Those boundaries are part of the announcement and must remain part of the reported claim. [1]
Barth syndrome is described by FDA as a rare, serious, life-threatening mitochondrial disease. The announcement discusses fatigue, poor stamina and exercise intolerance among survivors into adolescence and adulthood. This is a disease context, not evidence for an anti-aging program in healthy people. [1]
FDA says Forzinity binds to the inner part of mitochondria and improves mitochondrial structure and function. That mechanism is attributed to the product announcement. It should not be converted into a general claim that any marketed mitochondrial peptide improves daily energy. [1]
The accelerated pathway can permit earlier approval using a measure reasonably likely to predict benefit without directly measuring the ultimate patient benefit. The route is an evidence distinction, not shorthand for either no evidence or complete certainty. [1]
For this approval, FDA cites improved strength of the muscle used to straighten the knee. It considered that measure reasonably likely to predict benefits such as easier standing or farther walking. The exact endpoint matters when explaining what was observed and what remains to be confirmed. [1]
FDA requires a post-approval randomized, double-blind, placebo-controlled trial to confirm that changes in knee-muscle strength translate into patient benefit. A careful article therefore includes the follow-up requirement instead of ending the story at the word approved. [1]
Compounding is a separate question
FDA maintains a page on certain bulk drug substances for compounding that may present significant safety risks. This is an official warning source, not a marketplace comparison or a performance ranking. Its entries should be read individually. [2]
For BPC-157, the page discusses potential immunogenicity and difficulties involving peptide-related impurities and active-ingredient characterization. It also states that FDA has limited or no safety information for proposed routes and cannot determine whether the substance would harm humans. That is a safety-information gap, not a favorable verdict. [2]
For CJC-1295, FDA describes limited clinical data and identified serious adverse events, including increased heart rate and systemic vasodilatory reactions. A mechanism or a seller's anecdote does not answer those concerns. The route, exposure and product still matter. [2]
The page discusses substances with different issues and different available information. One molecule's warning cannot be copied mechanically to another; neither can silence about a specific substance be treated as approval. Regulatory reporting requires checking the actual entry. [2]
A compounded product and an FDA-approved manufactured product are not the same regulatory object. A source about one cannot certify the other. The catalog's warning that evidence labels do not guarantee the purity or contents of a gray-market vial remains essential.
Reading the catalog responsibly
The catalog's labels are an authored summary, not a validated universal evidence-grading system. They may help navigate the list, but the underlying sources and stated verification limits carry more weight than the numerical level assigned to a compound.
The catalog explicitly notes that some items were not individually verified. Republishing it preserves that caveat; it does not erase it. This note does not pretend that the complete catalog now has claim-by-claim clinical review.
A useful evidence card would distinguish mechanism, human findings, regulatory decision, product-specific quality and unknowns. These fields prevent a trial result or approval announcement from laundering unrelated vendor claims into the same apparent authority.
What is still unfinished
A complete refresh would require reviewing every compound's current official label or trial record, identifying the indication and route, and separating finished-product evidence from molecule-level discussion. That remains work in progress; no blanket peptide recommendation is made.
The defensible conclusion is product-specific. Some treatments have defined regulatory evidence, some substances have explicit safety concerns and many catalog claims remain unresolved. The full catalog is retained below, while this note adds boundaries that keep those states from collapsing into one promise. Nothing here is treatment, dose, vendor or self-administration advice.
The complete compound catalog
Risk levels
The levels are an authored summary of approval status and amount of research. They rate the evidence behind the molecule, not the safety of a gray-market vial, whose purity and contents are not guaranteed.
Weight loss
Type 2 diabetes, weight loss, heart risk reduction (Ozempic, Wegovy). FDA-approved. Large trials. Vendor vials are not the approved product.
Level 1Type 2 diabetes, weight loss, sleep apnea (Mounjaro, Zepbound). FDA-approved. Large trials. Vendor vials are not the approved product.
Level 1Weight loss (GLP-1, GIP and glucagon triple agonist). Not approved anywhere as of 17 Nov 2026. Multiple phase 3 trials reported positive results in 2026; Lilly plans an FDA filing in Q1 2027. Not eligible for compounding (not an approved drug and not on FDA bulks lists); regulators and the manufacturer warn against unapproved products.
Level 3Weight loss and type 2 diabetes (GLP-1 and glucagon). Approved in China (June 2025). Not approved in the US.
Level 2Weight loss and fatty liver disease (GLP-1 and glucagon). Not approved. Phase 3 obesity result reported; FDA breakthrough designation for MASH.
Level 3Weight loss (long-acting amylin analog), mainly studied with semaglutide. Not approved on its own as of 17 Nov 2026; late-stage trials are mostly as the CagriSema combination.
Level 3Weight loss (CagriSema). Not approved as of 17 Nov 2026. Novo Nordisk submitted an FDA application in December 2025 after positive phase 3 trials; a decision was expected in Q4 2026.
Level 3Weight loss, vendor-made pairing. Not an approved or human-studied product. A 2026 preclinical rat study of the retatrutide plus cagrilintide combination exists; there is no human trial of this exact pairing.
Level 5Weight loss, vendor-made pairing. Not a studied product. No human trial of this exact pairing exists; it combines two drugs, one unapproved.
Level 5Fat loss (fragment of growth hormone). Not approved. Human obesity trials did not show a clear benefit. Previously placed in FDA compounding category 2; the nomination was later withdrawn, and FDA's stated safety concerns remain on record.
Level 4Fat loss (enzyme inhibitor). A small molecule, not a peptide. Not approved. Mouse studies only.
Level 5Weight loss. A small molecule, not a peptide. Not FDA-approved. Phase 2 and 3 obesity trials; side effects include raised heart rate and blood pressure.
Level 3Recovery / healing
Tendon, gut and tissue healing (stomach-derived peptide). Not approved. Mostly rat studies, very few small human reports. Previously in FDA compounding category 2 (nomination later withdrawn). An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers subcutaneous, intramuscular, oral and topical forms while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug.
Level 5Tissue repair (fragment of thymosin beta-4). Not approved. Animal data. Previously in FDA compounding category 2 (nomination later withdrawn). An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers subcutaneous and intramuscular injectable forms while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug. Banned in sport.
Level 5Tissue repair, sold as a pair. Not a studied product; no human study of the paired product found. Each part has mainly animal data.
Level 5Nerve pain and tissue repair (EPO-related). Not approved. Small phase 2 trials in neuropathy and sarcoidosis.
Level 4Growth hormone
Reduces belly fat in HIV lipodystrophy (Egrifta). FDA-approved for that use only. Vendor vials are not the approved product.
Level 1Growth hormone deficiency testing and treatment. Formerly FDA-approved (Geref); the maker stopped selling it in the US. Compounded versions exist.
Level 2Raises growth hormone (releaser). Not approved. A phase 2 trial for post-surgery gut recovery was stopped. FDA category 2 (503B).
Level 4Raises growth hormone (short-acting). Not approved. Small early human studies. Previously placed in FDA compounding category 2; the nomination was later withdrawn, and FDA's stated safety concerns remain on record.
Level 4Raises growth hormone (long-acting). Not approved. Small early human studies. Previously placed in FDA compounding category 2; the nomination was later withdrawn, and FDA's stated safety concerns remain on record.
Level 4Raises growth hormone, common pairing. Not a studied product; no human study of the paired product found. Each part has limited human data.
Level 5Raises growth hormone, vendor pairing. Not a studied product; no human study of the paired product found. Only tesamorelin is approved, alone.
Level 5Raises growth hormone and appetite. Not approved. Short human studies of hormone release.
Level 4Raises growth hormone (stronger than GHRP-6). Not approved. Short human studies. On FDA compounding category 2 for injectable and nasal routes (503B).
Level 4Raises growth hormone; studied for heart effects. Not approved. Small human studies.
Level 4Muscle growth (long-acting IGF-1 analog). Not approved. Used in cell culture and animal work. Banned in sport.
Level 5Muscle growth (shortened IGF-1). Not approved. Essentially laboratory and animal data.
Level 5Muscle repair (splice form of IGF-1). Not approved. Cell and animal data. PEG-MGF was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 5Muscle growth (blocks myostatin). A protein, not a short peptide. Not approved. Human trial in Duchenne stopped in 2011 for nosebleeds and skin vessel changes.
Level 4Muscle growth (blocks myostatin). Not approved. Gene-therapy trials exist; injectable protein vials are not a studied drug.
Level 5Muscle growth (blocks myostatin). Not approved. Same as Follistatin 315.
Level 5Appetite and growth hormone release (the hunger hormone). Not approved. Small clinical studies in wasting and gut motility.
Level 4Listed with growth products. Myostatin is the body's own brake on muscle growth. No therapeutic use known. Drugs that block it are the ones studied.
Level 5Anti-aging / skin
Skin repair and wound healing (copper peptide). Not an approved drug. Used in cosmetics; small studies of topical use. The injectable form was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 4Tanning; also studied for erectile function. Not approved. Small trials only. Case reports of mole changes and other serious events. Melanotan II was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 4Tanning pigment (melanin). The same compound, afamelanotide, is FDA-approved as Scenesse, an implant for light-sensitivity in EPP. Vials are not that product.
Level 1Topical wrinkle ingredient. Cosmetic ingredient, not a drug. Small manufacturer-run studies.
Level 5Cognitive / neuro
Anxiety (nasal spray). Approved in Russia. Not approved in the US. Selank was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 2Stroke recovery and cognition (nasal spray). Approved in Russia. Not approved in the US. Semax was placed in FDA compounding category 2; the nomination was later withdrawn. An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers intranasal use while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug.
Level 2Anxiety and cognition, pairing. Not a studied product; no human study of the paired product found.
Level 5Sleep and stress. Not approved. Small, mixed human sleep studies. Emideltide (DSIP) was placed in FDA compounding category 2; the nomination was later withdrawn. In July 2026 an FDA advisory committee voted against recommending it for pharmacy compounding, and it is not covered by HHS's draft October 2026 enforcement-discretion policy.
Level 4Memory and brain-cell connections. Not approved. Animal studies only. FDA has found no human exposure data.
Level 5Wakefulness and appetite (brain signal). Research use only. Drugs that block orexin are approved for insomnia.
Level 5Wakefulness and appetite (brain signal). Research use only.
Level 5Memory and nerve growth (derived from CNTF). Not approved. Animal studies.
Level 5Depression (fragment of spadin). Not approved. Mouse studies; no human data.
Level 5Hair growth research (Wnt pathway). Not approved. Cell and mouse work.
Level 5Immune / inflammation
Immune support; used in hepatitis and some cancers. Approved in many countries (Zadaxin). Not approved in the US. Thymosin alpha-1 was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 2Immune regulation (thymus extract peptide). Used in Russia. Evidence largely from its developers' group.
Level 2Infection defense and wound healing. Not approved. Small early trial in leg ulcers. LL-37 was placed in FDA compounding category 2; the nomination was later withdrawn.
Level 4Gut and skin inflammation (piece of a-MSH). Not approved. Animal studies; FDA has found no human exposure data. An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers topical and oral forms while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug.
Level 5Inflammation, lung and gut conditions. Not approved in the US. The drug form, aviptadil, was tested in lung disease without approval.
Level 4Antioxidant; sold for immunity and skin brightening. Made by the body. Sold as a supplement; not an approved drug for these uses. Small studies.
Level 4Stress hormone fragment. Related ACTH products are FDA-approved (Acthar for infantile spasms; cosyntropin as a diagnostic test). The 1-34 fragment as sold is not one of them.
Level 2Cancer cell research peptide. Not approved. Cell and animal studies.
Level 5Sexual health / hormones
Low sexual desire in premenopausal women (Vyleesi). FDA-approved for that use. Vendor vials are not the approved product.
Level 1Labor induction and postpartum bleeding (Pitocin). Also studied for social behavior. FDA-approved injection for labor use. Nasal use for mood or bonding is unproven.
Level 1Fertility treatment; low testosterone in men with pituitary causes. FDA-approved for those uses. Used with testosterone therapy off-label.
Level 1Triggers LH and FSH; used with testosterone therapy. Formerly FDA-approved as a diagnostic (Factrel); no longer sold in the US.
Level 2Starts the reproductive hormone chain; fertility. Not approved. Small human studies. Kisspeptin-10 is on FDA category 2.
Level 4GnRH agonist for fertility and endometriosis. Used as a drug in some countries such as China. Not approved in the US.
Level 2GnRH agonist implant. Approved for animals (veterinary implants). Not an approved human drug in the US.
Level 2GnRH agonist for prostate cancer and fertility. Not a bioregulator. Approved as a drug in many countries. Not marketed in the US.
Level 2Metabolic / longevity
Mitochondrial disease; muscle strength in Barth syndrome. FDA accelerated approval as Forzinity on September 19, 2025, for Barth syndrome in patients weighing at least 30 kg, with a required post-approval confirmatory trial. Not an approval for any other use.
Level 1Metabolism ('exercise mimic'). Not approved. Mostly animal data; an analog had only early human trials. MOTS-c was placed in FDA compounding category 2; the nomination was later withdrawn. An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers subcutaneous and intramuscular injectable forms while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug.
Level 5Longevity; telomeres. Not approved. Evidence is cell, animal and the developer's own studies. Epitalon was placed in FDA compounding category 2; the nomination was later withdrawn. An FDA advisory committee recommended it for pharmacy compounding in July 2026; HHS's draft October 2026 enforcement-discretion policy covers subcutaneous and intramuscular forms dispensed in intermittent courses while rulemaking proceeds. Neither is a final rule, and it is still not an FDA-approved drug.
Level 5Cell energy; sold as an anti-aging infusion. A natural coenzyme, not an approved drug. Small studies of precursors; infusion claims are unproven.
Level 4Brain and metabolic protection. Not approved. Cell and animal data.
Level 5Clears aged cells (senolytic). Not approved. Cell and mouse studies.
Level 5Exercise mimic. A small molecule, not a peptide. Not approved. Mouse studies.
Level 5Destroys blood supply to fat. Not approved. Monkey studies showed kidney toxicity. The one human trial (NCT01262664) was terminated early at the investigator's request.
Level 5Exercise mimic. A nucleoside, not a peptide. Not approved. Failed a large heart-surgery trial. Banned in sport.
Level 4Bioregulators (Russian short peptides)
Marketed for lungs and bronchi. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for bronchial lining. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the heart. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for cartilage. Cell-culture data; no human trial and no joint study despite the name.
Level 5Marketed for the brain cortex. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the brain. Cell and rat studies from the developer's lab. No controlled human trial.
Level 5Marketed for the hypothalamus. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the pituitary. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the liver. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the liver and gut. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the pancreas. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the prostate. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the testes. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for blood vessels. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the eye and retina. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Marketed for the immune system. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Thymus hormone, marketed for immunity. Marketed for one organ system by Russian developers; evidence is cell and animal work plus studies from the developer's own institute.
Level 5Immune modulator (the dipeptide Glu-Trp). Used in Russia. Failed a US phase 3 in Kaposi's sarcoma as IM862.
Level 4Pituitary signal to the thyroid. Not a bioregulator. The recombinant form, Thyrogen, is FDA-approved for thyroid cancer follow-up.
Level 1Named on the site. I could not confirm what each is marketed for. Treat as unstudied. No approvals or human trials found.
Level 5Sources
Peptide list and category names: peptide-compare.com, read 3 Oct 2026. FDA compounding category 2 list: fda.gov. FDA advisory committee briefing, July 2026: fda.gov. Forzinity approval: fda.gov. Mazdutide, China: Innovent. Retatrutide filing plan: BioPharma Dive. FDA compounding advisory committee, 23-24 July 2026: fda.gov. HHS draft enforcement-discretion policy for six peptides, 30 October 2026: Federal Register.
Checked 3 Oct 2026. Items without a linked source above are from standard drug labels and general knowledge, not individually verified. Ask a doctor before using any of these.
Sources and further reading
- FDA grants accelerated approval for first treatment for Barth syndromeU.S. Food and Drug Administration · 19 September 2025
- Certain bulk drug substances for use in compounding that may present significant safety risksU.S. Food and Drug Administration
- Peptide catalog with prices and risk levelspeptide-compare.com · read 3 Oct 2026
- FDA advisory committee briefing document, July 2026U.S. Food and Drug Administration
- Meeting of the Pharmacy Compounding Advisory Committee, 23-24 July 2026U.S. Food and Drug Administration
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug SubstancesFederal Register · 30 October 2026
- Novo Nordisk submits CagriSema NDA to FDANovo Nordisk · 18 December 2025